Cellular Biomedicine Group Inc. Logo
Cellular Biomedicine Group Announces Positive 48-Week Clinical Data of AlloJoin™ Human Adipose-Derived Mesenchymal Progenitor Cell (haMPC) Knee Osteoarthritis (KOA) China Phase I Trial
March 16, 2018 07:00 ET | Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., March 16, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...
Cellular Biomedicine Group Inc. Logo
Cellular Biomedicine Group Announces Three-Month Interim Safety Data from Phase I Clinical Trial for AlloJoin™ Off-the-Shelf Allogeneic Stem Cell Therapy for Knee Osteoarthritis
December 09, 2016 08:00 ET | Cellular Biomedicine Group Inc.
- No Serious Adverse Events Observed- SHANGHAI, China and CUPERTINO, Calif., Dec. 09, 2016 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a...
Cellular Biomedicine Group Inc. Logo
Cellular Biomedicine Group Announces Positive 48-Week Data From Phase IIb Clinical Trial for Knee Osteoarthritis Stem Cell ReJoin® Therapy
January 13, 2016 08:00 ET | Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Jan. 13, 2016 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...
Cellular Biomedicine Group Inc. Logo
Cellular Biomedicine Group Launches Phase I Clinical Trial for AlloJoin™ Off-the-Shelf Allogeneic Stem Cell Therapy for Knee Osteoarthritis
January 06, 2016 09:03 ET | Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a biomedicine firm engaged in the development of...